Study to Assess the Safety of Treatment of Articular Cartilage Lesions With CartiLife®

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 17, 2012

Primary Completion Date

December 10, 2013

Study Completion Date

December 10, 2013

Conditions
Articular Cartilage Lesion of Knee
Interventions
DRUG

CartiLife

Biological: CartiLife® Procedure: CartiLife® is beads (1.0 to 1.5 mm in diameter) in suspension, developed from autologous chondrocytes. The beads are implanted in a volume of 1 cm3 per the capacity of the syringe to the affected area through injection with a fibrin adhesive through minimal arthrotomy.

Sponsors
All Listed Sponsors
collaborator

Kyung Hee University Hospital

OTHER

lead

Biosolution Co., Ltd.

INDUSTRY